EPSOLAY SIDE EFFECTS

  • Generic Name: benzoyl peroxide topical cream
  • Brand Name: Epsolay
  • Drug Class: Acne Agents, Topical
Last updated on MDtodate: 10/04/2022

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two randomized, double-blind, vehicle-controlled trials, adult subjects with rosacea applied EPSOLAY (N = 488) or vehicle (N = 234) once daily for 12 weeks. The majority of subjects were Caucasian (93%) and female (73%) with a mean age of 51 years.

Table 1 presents the most common adverse reactions occurring in ≥ 1% of subjects treated with EPSOLAY and more frequently than in subjects treated with vehicle.

Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects Treated with EPSOLAY and with Greater Frequency than Subjects Treated with Vehicle

EPSOLAY
N=488
Vehicle
N=234
Application site pain 11 (2%) 2 (1%)
Application site erythema 11 (2%) 2 (1%)
Application site pruritus 6 (1%) 1 (<1%)
Application site edema* 4 (1%) 0 (0%)
* Application site edema includes: application site swelling and application site edema

 

During the clinical trials, local tolerability evaluations were conducted at baseline and at each study visit by assessment of dryness, itching, scaling and stinging/burning. Table 2 presents the local tolerability assessments by severity grade at Week 12.

Table 2: Facial Cutaneous Tolerability Assessment

Sign/Symptom EPSOLAY
N=455*
Severity at Week 12
Mild Moderate Severe
Dryness 25% 7% 0%
Itching 24% 6% 0%
Scaling 13% 4% 0%
Stinging/ Burning 20% 3% 1%
* Of the 488 subjects treated with EPSOLAY, 455 subjects had local tolerability assessments at Week 12.

 

In a 40-week open-label extension safety study (for a total of up to 52 weeks of treatment) the frequency and severity of local tolerability signs and symptoms at Week 52 were comparable to those reported at Week 12.

 

SRC: NLM .